Redefining preclinical digestion & gut microbiome research
Whenever you find yourself on the side of the majority, it is time to reform (or pause and reflect).Mark Twain
Since the 90’s, traditional in vitro gastrointestinal research methods have stagnated. Especially for gut microbiome research, such models rely on slow, labour-intensive and expensive tools with limited interpretability. As a result, you have to compromise on either the scope of the study (i.e. number of products tested) or on the robustness and significance of it (addressing interindividual variability within a population). At Cryptobiotix, we think different: why not combine quality and quantity? We thrive on redefining established processes, both in the lab and in thinking. Challenge us with your research question and let us customise the most suitable path forward in your early and late R&D stages of product development.
There are three key aspects in how we work:
- Increase biorelevance
- Increase throughput by miniaturisation
- Clarify the key findings through advanced data interpretation
Cryptobiotix is a CRO in the gastrointestinal field that provides state-of-the-art preclinical research services using the SIFR® (“cipher”) and D-SIFR® (“decipher”) technologies. They combine in vitro and ex vivo approaches to enable you to investigate more products, in a statistically robust design that considers biological variation.
We answer research questions pertaining to:
- upper gastrointestinal digestion and absorption
- interplay with the gut microbiota and host-microbiome interactions
We use those biorelevant, high-throughput models to generate an unprecedented amount of data, that we analyse, interpret and report.
- Screening & ranking of candidates before clinical trials
- In-depth characterisation of promising lead product
- Generation and protection of IP
- Support your claims
Relying on the latest published insights in digestion and gut microbiome research, the SIFR and D-SIFR technologies address various questions pertaining to digestion and fermentation. Complementing high biorelevance with operational standardisation, this high-throughput technology allows you to allocate your preclinical budget optimally from early candidate screening to in-depth lead product characterisation.